Chair: J. Benítez, ES - R. Eeles, UK - H. Vasen, NL
It is our pleasure to welcome you again to the fifth Madrid Familial Cancer Conference that since 2004 we hold every two years. The present Conference, hosted at the Spanish National Cancer Research Centre (CNIO) aims to present recent advances in this field from a multidisciplinary point of view. During this decade, familial cancer has become an important challenge for oncologists, geneticists and molecular biologists, due to its implications not only at the individual but also at the familial and social level. This type of cancers affect several members of a single family, being the identification of high risk families, the knowledge of the genes responsible for specific diseases, the clinical follow up of mutation carriers, the development of new treatments and the discovery of tailored drugs, some of the different challenges involved. In most of European countries, the number of professionals working in this field has increased ten times over in the last years, demonstrating the interest that familial cancer has in our society. The Conference intends not only to cover and update numerous topics related to these genetic diseases but also to be a forum of discussion and meeting for professionals, either experienced clinicians and scientists or young people that are starting to work, or just interested in this exiting world.
Thank you all for coming to Madrid and we hope you enjoy a pleasant and successful Conference.
Javier Benitez, Hans Vasen, Rosalind Eeles
• To update recent advances in familial cancer
• To better define the genetic profile of these cancers and the clinical management of families and
• To analyze the impact of the new technologies and their contribution to familial cancer risk.
• General concepts in familial cancer: genetic variants, variants of unknown significance; modifier
factors; genetic counseling
• Common cancers: breast cancer and the family of breast cancer genes; selection criteria and
clinical management; new treatments; colorectal cancer and prostate cancer; genetic and
• Other hereditary syndromes: Familial pheocromocitoma; pancreatic cancer; Birt-Hogg-Dube
syndrome; familial melanoma.
• Rare tumors: Fanconi anemia; Dysqueratosis congenital; genetic syndromes of the RAS/MAP
pathway; li Fraumeni syndrome.
• New technologies applied to familial cancer studies: Integrative genomic analysis; cancer
genome and personalized medicine; whole exome sequencing in the search of high
The 4th Familial
Carolina Garcia Sabaté
Centro Nacional de Investigaciones Oncológicas (CNIO) - Scientific Events Office
Melchor Fernández Almagro, 3
E-28029 Madrid - Spain
Tel: +34 91 224 6900
Fax: +34 91 224 6980
European School of Oncology
Via del Bollo 4
20123 Milan - Italy
Tel: +39 02 8546 4523
Fax: +39 02 8546 4545
Centro Nacional de InvestigacionesOncológicas (CNIO)
Melchor Fernández Almagro, 3
E-28029 Madrid - Spain
The official language of the conference will be English. No simultaneous translation will be provided.
All participants will be issued with a certificate of attendance at the close of the conference.
The European School of Oncology will apply for CME credits to the Accreditation Council of Oncology in Europe (ACOE). Information on the status of the application can be obtained from the organising secretariat.
The badge is the only official evidence of registration and should be worn at all times during the conference. Loss of badge means loss of registration.
The organisers bear no responsibility for untoward events in connection with, before, during and after the conference. Participants are strongly advised to take out their own personal and travel insurance coverage.
15/05/2012: poster abstracts deadline
15/05/2012: registration deadline (after this date, registration will only be available on-site)
15/05/2012: cancellation deadline
24/05/2012: replacement deadline
A. Antoniou, University of Cambridge, UK
J. Benítez, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
G. Capellá, Instituto Catalan Oncologia, Barcelona, ES
A. Cascón, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
A. Castells, Hospital Clínic, Barcelona, ES
F. Dantzer, University of Strasbourg, FR
R. Eeles, The Royal Marsden Hospital, Sutton, UK
D. Eccles, Southampton University Hospital Trust, UK
T. Frebourg, Rouen University Hospital, FR
M.J. García, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
D. Goldgar, University of Utah, Salt Lake City, US
N. Gruis, Leiden University Medical Center, Leiden, NL
C. Guerra, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
S. Hodgson, St. George's Hospital Medical School, London, UK
F. Menko, VU University Medical Center, Amsterdam, NL
R. Milne, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
A. Osorio, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
R. Perona, Instituto Investigaciones Biomedicas, Madrid, ES
J. Reis Filho, Institute Cancer Research, London, UK
M. Robledo, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
D.H. Roukos, Ioannina University School of Medicine, Ioannina, GR
J. Surrallés, Universitat Autónoma de Barcelona, ES
M. Urioste, Centro Nacional de Investigaciones Oncológicas, Madrid, ES
H. Vasen, Leiden University Medical Centre, Leiden, NL
Hereditary cancer syndromes. Where do we go?
Genetic variants and familial cancer risk
|9:50||Modifier factors. Future applications |
A. Antoniou, UK
The problem of unknown variants
Picture, posters, coffee break
|Genetic counseling in familial cancer |
S. Hodgson, UK
|COMMON CANCERS I|
Chair: S. Hodgson, UK
The family of breast cancer genes
|12:20||Phenotype-genotype correlation in breast cancer |
J. Reis Filho, ES
|12:40||Pathological feature of endometrial cancer in Lynch syndrome |
J. Palacios, ES
|PARP inhibitors. Progress in cancer therapy |
F. Dantzer, FR
H. Vasen, NL - D. Eccles, UK
COMMON CANCERS II
(Epi) genetics and clinical management of Lynch syndrome
The genetics bases of FAP syndorme
|9:10||Management of APC families including MUTYH families|
A. Castells, ES
Familial prostate cancer. Genetics and clinical management
OTHER HEREDITARY CANCER SYNDROMES
Genetic heterogeneity of Familial Pheocromocitoma
Pancreatic cancer. Genetics and clinical management
|11:30||Birt-hogg-Dube syndrome. Diagnosis and clinical management |
F. Menko, NL
|11:50||Clinical and genetic characteristics in familial malignant melanoma |
N. Gruis, NL
M. Robledo, ES
|14:35||Dyskeratosis congenita |
|14:55||Genetic syndromes of the RAS/MAP pathway |
C. Guerra, ES
|LiFraumeni syndrome. From molecular bases to clinical management |
T. Frebourg, FR
|NEW TECHNOLOGIES APPLIED TO FAMILIAL CANCER STUDIES|
Chair: A. Osorio, ES
Identification of novel targets and regions through integrative genomic analysis
|The clinical potential of sequencing cancer genomes for personalized medicine|
D.H. Roukos, GR
|Whole exome sequencing in the search of high susceptibility genes |
A. Cascón, ES
APPLICATION AND ABSTRACT SUBMISSION
You may apply and submit your abstract to the organising secretariat online at:
Instructions for application and abstract submission
Participants with new data relevant to the subject of the conference may submit one abstract to be considered for poster presentation. Only papers whose abstracts have been reviewed and approved by the conference coordinators will be presented.
Abstracts should be written in English and the text should not exceed 3000 characters, title included.
The title should appear in capital letters.
For each author, type surname first, followed by first name and initials (presenting author in capital letters).
List of affiliations after the author's list.
Indicate 3-5 keywords at the end of the text.
The full address with telephone, fax number and email of the corresponding author must be provided. The corresponding author will receive all the subsequent communication concerning this abstract. Please also indicate your approval for publication in case the abstracts are issued
in a journal.
Eight abstracts will be selected for the oral presentation. We will notify it to the first author before May 15th.
It is the responsibility of the presenting author to ascertain whether all authors are aware of the content of the abstract before submission.
THE POSTER ABSTRACTS DEADLINE IS 15 MAY 2012